Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer (6137p)

This study has been terminated.
(Low accrual and PI leaving the institution.)
Sponsor:
Collaborators:
Fred Hutchinson Cancer Research Center
Novartis
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance
ClinicalTrials.gov Identifier:
NCT01011075
First received: October 14, 2009
Last updated: July 24, 2012
Last verified: July 2012

October 14, 2009
July 24, 2012
August 2009
July 2010   (final data collection date for primary outcome measure)
To estimate the clinical efficacy of the combination of weekly paclitaxel and intermittent imatinib in elderly patients with advanced non-small cell lung cancer. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01011075 on ClinicalTrials.gov Archive Site
To evaluate the safety profile of the combination of weekly paclitaxel and intermittent imatinib in elderly patients with advanced non-small cell lung cancer. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Non-small Cell Lung Cancer
Drug: Gleevec, paclitaxel

Each 28-day cycle includes three weekly doses of intravenous paclitaxel, administered on Day 3,10, and 17.

Each 28-day cycle includes 12 daily doses of oral Gleevec (imatinib mesylate). Imatinib is administered in four-day pulses. Pulses bracket each paclitaxel infusion as follows: Days 1-4, Days 8-11, Days15-18. Each imatinib dose is 600 mg.

Other Names:
  • Imatinib mesylate
  • gleevec
  • paclitaxel
Not Provided
Bauman JE, Eaton KD, Wallace SG, Carr LL, Lee SJ, Jones DV, Arias-Pulido H, Cerilli LA, Martins RG. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer. 2012 Oct 3;12:449. doi: 10.1186/1471-2407-12-449.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
3
July 2012
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥ 70 years
  • Histologic or cytologic diagnosis of non-small cell lung cancer
  • At least one site of measurable disease, as defined by the modified RECIST criteria (See section 7.6)
  • Stage IIIB with pleural effusion or Stage IV disease. Includes patients who received surgery alone for early stage disease, now in relapse with advanced disease. Staging is according to the American Joint Committee on Cancer classification scheme, 6th edition.48
  • Adequate hepatic, renal and marrow function

    • Liver function tests: total bilirubin < 1.25 x upper limit of normal (ULN), AST and ALT < 2.5 x ULN, Creatinine < 1.5 x ULN
    • Baseline absolute neutrophil count > 1500/μL
    • Baseline platelet count > 100,000/μL
  • ECOG Performance Status 0, 1 or 2 at the time of informed consent. (See Appendix 1)
  • Written, voluntary consent
  • Patients with reproductive potential must use an acceptable contraceptive method. Such methods include: 1) Male hormonal contraception; 2) Partner without reproductive potential, including post-menopausal status or history of tubal ligation; 3) Partner with ntrauterine device (IUD) or contraceptive vaginal ring; 4) Partner takes oral contraceptive pill, wears contraceptive patch, or has contraceptive implant; 5) Routine use of barrier method, such as condoms or diaphragm, during sexual intercourse.

Exclusion Criteria:

Uncontrolled brain metastasis. Patients with known brain metastasis must have completed treatment with surgery, radiation or both. In addition, they must be off corticosteroids.

  • Symptomatic neuropathy (Grade 2 or higher)
  • Prior chemotherapy for advanced non-small cell lung cancer. (Prior adjuvant, neoadjuvant, or chemoradiotherapy for NSCLC is permitted, provided at least 6 months elapsed prior to documented metastatic recurrence.)
  • Patient is < 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active intervention
  • Prior radiation therapy to > 25% of bone marrow
  • Grade III/IV congestive heart failure, as defined by NYHA criteria, or myocardial infarction within 6 months.
  • Any serious or uncontrolled concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
  • Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis or cirrhosis.
  • Major surgery two weeks prior to study treatment
  • Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent
  • Any condition requiring continuous administration of systemic corticosteroids.
  • The patient is on therapeutic anti-coagulation with warfarin.
Both
70 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01011075
INST CST1571BUS240
Yes
New Mexico Cancer Care Alliance
New Mexico Cancer Care Alliance
  • Fred Hutchinson Cancer Research Center
  • Novartis
Principal Investigator: Julie Bauman, MD University of New Mexico Cancer Center
New Mexico Cancer Care Alliance
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP